Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 9/20 | 0.39 |
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 9/20 | 0.39 |
| ▸ | CA9 | Q16790 | 9/20 | 0.39 |
| ▸ | CA7 | P43166 | 7/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705632 | 0.89 | TSHR (0.42) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL297916 | 0.83 | TSHR (0.59) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL27926059 | 0.80 | TSHR (0.56) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL29220140 | 0.79 | TSHR (0.48) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL21194066 | 0.78 | TSHR (0.36) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL11510451 | 0.78 | TSHR (0.53) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL16048299 | 0.78 | TSHR (0.53) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL20565358 | 0.78 | TSHR (0.53) | TSHRADRA1APDE4DCA12CA1 | |
| SCHEMBL1462514 | 0.78 | TSHR (0.38) | TSHRADRA1APDE4DALDH1A1 | |
| SCHEMBL1088971 | 0.76 | TSHR (0.40) | TSHRADRA1APDE4DCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487602-B2 | Furan based resin, process for the preparation thereof, and use of the compound | DSM IP ASSETS B.V. (NL) | 2016-11-08 | — | — | US | claimed |
| US-20130109822-A1 | FURAN BASED RESIN, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THE COMPOUND | DSM IP ASSETS B.V. (NL) | 2013-05-02 | — | — | US | claimed |
| US-20110306735-A1 | PROCESS FOR THE PREPARATION OF A HYDROXY-AROMATIC RESIN; HYDROXY-AROMATIC RESIN, AND MODIFICATION THEREOF | DSM IP ASSETS B.V. (NL) | 2011-12-15 | — | — | US | claimed |
| US-20110021740-A1 | FURAN BASED RESIN, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THE COMPOUND | DSM IP ASSETS B.V. (NL) | 2011-01-27 | — | — | US | claimed |
| EP-2222656-A1 | FURAN BASED RESIN, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THE COMPOUND | DSM IP Assets B.V. (NL) | 2010-09-01 | — | — | EP | claimed |
| US-20090203851-A1 | Process for the Preparation of a Hydroxy-Aromatic Resin: Hydroxy-Aromatic Resin, and Modification Thereof | DSM IP ASSETS B.V. (NL) | 2009-08-13 | — | — | US | claimed |
| WO-2009077587-A1 | FURAN BASED RESIN, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THE COMPOUND | DSM IP ASSETS B.V. (NL) | 2009-06-25 | — | — | WO | claimed |
| EP-2024317-A2 | PROCESS FOR THE PREPARATION OF A HYDROXY-AROMATIC RESIN; HYDROXY-AROMATIC RESIN, AND MODIFICATION THEREOF | DSMIP Assets B.V. (NL) | 2009-02-18 | — | — | EP | claimed |
| WO-2007140941-A2 | PROCESS FOR THE PREPARATION OF A HYDROXY-AROMATIC RESIN; HYDROXY-AROMATIC RESIN, AND MODIFICATION THEREOF | DSM IP ASSETS B.V. (NL) | 2007-12-13 | — | — | WO | claimed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-9765022-B2 | Disulfide compounds for delivery of pharmaceutical agents | TUFTS UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20050176916-A1 | Nitrogen-containing compound, the preparation thereof and application in amino-aldehyde resins | DSM I.P. ASSETS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| EP-1507770-A2 | NITROGEN-CONTAINING COMPOUND, THE PREPARATION THEREOF AND APPLICATION IN AMINO-ALDEHYDE RESINS | DSM IP Assets B.V. (NL) | 2005-02-23 | — | — | EP | disclosed |
| WO-2004110614-A1 | ENCAPSULATED MATERIALS | DSM IP ASSETS B.V. (NL) | 2004-12-23 | — | — | WO | disclosed |
| WO-2003101973-A2 | NITROGEN-CONTAINING COMPOUND, THE PREPARATION THEREOF AND APPLICATION IN AMINO-ALDEHYDE RESINS | DSM IP ASSETS B.V. (NL) | 2003-12-11 | — | — | WO | disclosed |
| US-6348617-B1 | REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0937703-A1 | METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | TSHR 1491/4885ADRA1A 4812/4885PDE4D 3623/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | TSHR 1491/4885ADRA1A 4812/4885PDE4D 3623/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | TSHR 1491/4885ADRA1A 4812/4885PDE4D 3623/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | TSHR 1390/4885ADRA1A 4793/4885PDE4D 3412/4885 |
| US-20090203851-A1 | Process for the Preparation of a Hydroxy-Aromatic Resin: Hydroxy-Aromatic Resin, and Modification Thereof | HRH3, HRH1, C9 | TSHR 3620/4885ADRA1A 94/4885PDE4D 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.